UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 489

Sortiert nach

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Volltextzugriff (PDF)

Design and testing of a humanized porcine donor for xenotransplantation

Nature (London), 2023-10, Vol.622 (7982), p.393-401

2023

Volltextzugriff (PDF)

Signal Grass (Brachiaria decumbens) Toxicity in Grazing Ruminants

Agriculture (Basel), 2015-12, Vol.5 (4), p.971-990

Low, Susan

2015

Volltextzugriff (PDF)

Prolonged activity of factor IX as a monomeric Fc fusion protein

Blood, 2010-03, Vol.115 (10), p.2057-2064

2010

Volltextzugriff (PDF)

Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-Human Primates through an Immunoglobulin Transport Pathway

Proceedings of the National Academy of Sciences - PNAS, 2004-06, Vol.101 (26), p.9763-9768

2004

Volltextzugriff (PDF)

Reduction of IgG in Nonhuman Primates by a Peptide Antagonist of the Neonatal Fc Receptor FcRn

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (7), p.2337-2342

2008

Volltextzugriff (PDF)

Using Group Collaborative Investigations to Develop Pasture Biomass Prediction Equations

International Journal of Innovation in Science and Mathematics Education, 2021, Vol.29 (4)

2021

Volltextzugriff (PDF)

The Value of Student-led Field Trials for Agronomic Industry Training

International Journal of Innovation in Science and Mathematics Education, 2021, Vol.29 (4)

2021

Volltextzugriff (PDF)

PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn

Bioorganic & medicinal chemistry letters, 2011-11, Vol.21 (21), p.6332-6335

2011

Volltextzugriff (PDF)

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2006-01, Vol.20 (3), p.151-160

2006

Volltextzugriff (PDF)

Inhibitors of the FcRn:IgG Protein–Protein Interaction

The AAPS journal, 2009-09, Vol.11 (3), p.432-434, Article 432

2009

Volltextzugriff (PDF)

Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats

Bioconjugate chemistry, 2012-03, Vol.23 (3), p.518-526

2012

Volltextzugriff (PDF)

SECIS-SBP2 interactions dictate selenocysteine incorporation efficiency and selenoprotein hierarchy

The EMBO journal, 2000-12, Vol.19 (24), p.6882-6890

2000

Volltextzugriff (PDF)

Synthesis and Structure−Activity Relationships of Dimeric Peptide Antagonists of the Human Immunoglobulin G−Human Neonatal Fc Receptor (IgG−FcRn) Interaction

Journal of medicinal chemistry, 2010-02, Vol.53 (4), p.1587-1596

2010

Volltextzugriff (PDF)

A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Journal of controlled release, 2016-05, Vol.229, p.106-119

2016

Volltextzugriff (PDF)

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Science translational medicine, 2016-02, Vol.8 (325), p.325ra17

2016

Volltextzugriff (PDF)

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile

Science translational medicine, 2012-04, Vol.4 (128), p.128ra39

2012

Volltextzugriff (PDF)

The People, Place, and Space Reader

1, 2014

Volltextzugriff (PDF)

A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease

Journal of controlled release, 2019-06, Vol.303, p.34-41

2019

Volltextzugriff (PDF)

Abstract 3001: Accurins are endocytosed by KRAS-mutant cells via macropinocytosis

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3001-3001

2016

Volltextzugriff (PDF)

Cloning and Functional Characterization of Human Selenophosphate Synthetase, an Essential Component of Selenoprotein Synthesis (∗)

The Journal of biological chemistry, 1995-09, Vol.270 (37), p.21659-21664

1995

Volltextzugriff (PDF)

Abstract B25: Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy

Molecular cancer research, 2020-10, Vol.18 (10_Supplement), p.B25-B25

2020

Volltextzugriff (PDF)

Abstract 5602: VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5602-5602

2022

Volltextzugriff (PDF)

Abstract C184: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C184-C184

2015

Volltextzugriff (PDF)

A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Journal of controlled release, 2016-05, Vol.229, p.106-119

2016

Volltextzugriff (PDF)

1 – 25 von 489

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(362)
Mit Volltextzugriff
(434)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(486)
Japanisch
(52)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)
... seit 90 Tagen
(22)

Menü

Weitere Dienste

Einstellungen

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Design and testing of a humanized porcine donor for xenotransplantation

Signal Grass (Brachiaria decumbens) Toxicity in Grazing Ruminants

Prolonged activity of factor IX as a monomeric Fc fusion protein

Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-Human Primates through an Immunoglobulin Transport Pathway

Reduction of IgG in Nonhuman Primates by a Peptide Antagonist of the Neonatal Fc Receptor FcRn

Using Group Collaborative Investigations to Develop Pasture Biomass Prediction Equations

The Value of Student-led Field Trials for Agronomic Industry Training

PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

Inhibitors of the FcRn:IgG Protein–Protein Interaction

Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats

SECIS-SBP2 interactions dictate selenocysteine incorporation efficiency and selenoprotein hierarchy

Synthesis and Structure−Activity Relationships of Dimeric Peptide Antagonists of the Human Immunoglobulin G−Human Neonatal Fc Receptor (IgG−FcRn) Interaction

A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile

The People, Place, and Space Reader

A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease

Abstract 3001: Accurins are endocytosed by KRAS-mutant cells via macropinocytosis

Cloning and Functional Characterization of Human Selenophosphate Synthetase, an Essential Component of Selenoprotein Synthesis (∗)

Abstract B25: Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy

Abstract 5602: VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies

Abstract C184: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate

A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Suchergebnisse filtern